Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721603 · ClinicalTrials.gov registry record · Phase 2
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01721603 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 2 participants.
The verdict
NCT01721603, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a certain type of skin cancer (BRAFV600E melanoma) and brain metastases (tumors that have spread to the brain).
Interventions
- DRUG Trametinib
- DRUG Dabrafenib
- PROCEDURE Gamma Knife Radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721603
The ClinicalTrials.gov registry entry for NCT01721603 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trametinib is the first listed.
NCT01721603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721603 about?
NCT01721603 is a clinical study titled "Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets". The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a certain type of skin cancer (BRAFV600E melanoma) and brain metastases (tumo...
What is the current status of trial NCT01721603?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-04. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01721603?
The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), Gamma Knife Radiosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT01721603?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.